Answers are grounded in this paper and cite their sources.
Pilot case-control study reports circulating RKIP and pRKIP levels in lung cancer patients, highlighting their potential as non-invasive biomarkers.
Lung cancer (LC) is the leading cause of cancer-related deaths. Although low-dose computed tomography (LD-CT) reduces mortality, its clinical use is limited by cost, radiation, and false positives. Therefore, there is an urgent need for non-invasive and cost-effective biomarkers. The Raf Kinase Inhibitor Protein (RKIP) plays a crucial role in cancer development and progression and may also contribute to regulating the tumor-immune system axis. This protein has recently been described in biological fluids. Therefore, we conducted a pilot case-control study to assess RKIP and phosphorylated RKIP (pRKIP) levels in the urine and blood of LC patients.
No takes yet. Share an insight, caveat, or question.
Gasparri et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: